The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors
Open accessAbstract
Meprin is a zinc endopeptidase of the astacin family, which is expressed as a membrane-bound or secreted protein in mammalian epithelial cells, in intestinal leucocytes and in certain cancer cells. There are two types of meprin subunits, α and β, which form disulphide-bonded homo- and hetero-oligomers. Here we report on the cleavage of matrix proteins by hmeprin (human meprin) α and β homo-oligomers, and on the interactions of these enzymes with inhibitors. Despite their completely different cleavage specificities, both hmeprin α and β are able to hydrolyse basement membrane components such as collagen IV, nidogen-1 and fibronectin. However, they are inactive against intact collagen I. Hence the matrix-cleaving activity of hmeprin resembles that of gelatinases rather than collagenases. Hmeprin is inhibited by hydroxamic acid derivatives such as batimastat, galardin and Pro-Leu-Gly-hydroxamate, by TAPI-0 (tumour necrosis factor α protease inhibitor-0) and TAPI-2, and by thiol-based compounds such as captopril. Therapeutic targets for these inhibitors are MMPs (matrix metalloproteases), TACE (tumour necrosis factor α-converting enzyme) and angiotensin-converting enzyme respectively. The most effective inhibitor of hmeprin α in the present study was the naturally occurring hydroxamate actinonin (Ki=20 nM). The marked variance in the cleavage specificities of hmeprin α and β is reflected by their interaction with the TACE inhibitor Ro 32-7315, whose affinity for the β subunit (IC50=1.6 mM) is weaker by three orders of magnitude than that for the α subunit (Ki=1.6 µM). MMP inhibitors such as the pyrimidine-2,4,6-trione derivative Ro 28-2653 that are more specific for gelatinases do not bind to hmeprin, presumably due to the subtle differences in the mode of zinc binding and active-site structure between the astacins and the MMPs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tjäderhane, L., Buzalaf, M. A. R., Carrilho, M., & Chaussain, C. (2015) · Caries Research · doi:10.1159/000363582 · Cited by 2,306
Strategies for MMP inhibition in cancer: innovations for the post-trial era
Overall, C. M., & López-Otín, C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc884 · Cited by 1,349
Cited by
Remodelling the extracellular matrix in development and disease
Bonnans, C., Chou, J., & Werb, Z. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3904 · Cited by 4,367
Sather, S., Kenyon, K. D., Lefkowitz, J. B., Liang, X., Varnum, B. C., Henson, P. M., & Graham, D. K. (2007) · Blood · doi:10.1182/blood-2006-05-021634 · Cited by 332
Bauvois, B., & Dauzonne, D. (2006) · Medicinal Research Reviews · doi:10.1002/med.20044 · Cited by 266
The bone morphogenetic protein 1/Tolloid-like metalloproteinases
Hopkins, D. R., Keles, S., & Greenspan, D. S. (2007) · Matrix Biology · doi:10.1016/j.matbio.2007.05.004 · Cited by 259
Recent advances in MMP inhibitor design
Fisher, J. F., & Mobashery, S. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7894-9 · Cited by 215
Metadata
- Authors
- KRUSE, M.-N., BECKER, C., LOTTAZ, D., KÖHLER, D., YIALLOUROS, I., KRELL, H.-W., STERCHI, E. E., & STÖCKER, W.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2004-03-01
- Volume
- 378
- Issue
- 2
- Pages
- 383-389
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W1981567427
- Cited by
- 177
- References
- 2
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.